Table 3. Cox regression analysis of known prognostic parameters and MAGE expression in the whole cohort.
| Factor | n | HR | 95% CI | p value | ||
|---|---|---|---|---|---|---|
| T | T1 | 163 | 1 | 1 | 1 | |
| T2 | 168 | 2.216 | 1.485 | 3.305 | < 0.001 | |
| T3 | 107 | 2.999 | 1.985 | 4.532 | < 0.001 | |
| T4 | 79 | 4.766 | 3.134 | 7.246 | < 0.001 | |
| T1 | 163 | 1 | 1 | 1 | ||
| T2-4 | 354 | 2.929 | 2.055 | 4.174 | < 0.001 | |
| T1-2 | 331 | 1 | 1 | 1 | ||
| T3-4 | 185 | 2.368 | 1.815 | 3.089 | < 0.001 | |
| T1-3 | 438 | 1 | 1 | 1 | ||
| T4 | 79 | 2.540 | 1.867 | 3.457 | < 0.001 | |
| N | N0 | 256 | 1 | 1 | 1 | |
| N1 | 76 | 1.905 | 1.282 | 2.832 | 0.001 | |
| N2a | 25 | 1.820 | 0.99 | 3.346 | 0.054 | |
| N2b | 99 | 2.528 | 1.782 | 3.587 | < 0.001 | |
| N2c | 46 | 2.629 | 1.705 | 4.054 | < 0.001 | |
| N3 | 10 | 2.651 | 1.155 | 6.087 | 0.021 | |
| N0 | 254 | 1 | 1 | 1 | ||
| N1 | 78 | 1.723 | 1.156 | 2.568 | 0.008 | |
| N2 | 170 | 2.374 | 1.756 | 3.208 | < 0.001 | |
| N3 | 10 | 2.587 | 1.127 | 5.937 | 0.025 | |
| N0 | 254 | 1 | 1 | 1 | ||
| N+ | 258 | 2.168 | 1.639 | 2.868 | < 0.001 | |
| M | M0 | 500 | 1 | 1 | 1 | |
| M1 | 19 | 2.62 | 1.523 | 4.505 | < 0.001 | |
| Grading | 1 | 18 | 1 | 1 | 1 | |
| 2 | 274 | 1.223 | 0.537 | 2.786 | 0.631 | |
| 3 | 126 | 1.628 | 0.704 | 3.763 | 0.254 | |
| Treatment | Surgery | 446 | 1 | 1 | 1 | |
| Non-surgical | 66 | 3.012 | 2.189 | 4.146 | < 0.001 | |
| HPV | HPV DNA − | 481 | 1 | 1 | 1 | |
| HPV DNA + | 38 | 0.382 | 0.189 | 0.775 | 0.008 | |
| HPV, p16 − | 488 | 1 | 1 | 1 | ||
| HPV + p16 + | 26 | 0.414 | 0.184 | 0.932 | 0.033 | |
| Sex | female | 130 | 1 | 1 | 1 | |
| male | 389 | 0.793 | 0.589 | 1.068 | 0.127 | |
| Primary Site | Larynx | 169 | 1 | 1 | 1 | |
| Oral Cavity | 120 | 2.324 | 1.602 | 3.37 | < 0.001 | |
| Oropharynx | 167 | 1.787 | 1.255 | 2.545 | 0.001 | |
| Hypopharynx | 62 | 1.684 | 1.056 | 2.686 | 0.029 | |
| Smoking | Non-Smoker | 47 | 1 | 1 | 1 | |
| Smoker | 368 | 1.345 | 0.777 | 2.326 | 0.290 | |
| Non-smoker | 47 | 1 | 1 | 1 | ||
| < = 10 py | 25 | 1.044 | 0.452 | 2.412 | 0,920 | |
| > 10 < 20 | 44 | 0.931 | 0.437 | 1.98 | 0,852 | |
| > 20 < 30 | 75 | 1.141 | 0.596 | 2.186 | 0,690 | |
| > 30 < 40 | 81 | 1.134 | 0.599 | 2.147 | 0,700 | |
| > 40 | 143 | 1.809 | 1.020 | 3.208 | 0,043 | |
| Non-smoker | 47 | 1 | 1 | 1 | ||
| < median (36) | 162 | 1.025 | 0.569 | 1.847 | 0,935 | |
| > median (36) | 206 | 1.625 | 0.927 | 2.848 | 0,090 | |
| Non-Smoker | 47 | 1 | 1 | 1 | ||
| < 40 py | 163 | 1.017 | 0.564 | 1.834 | 0,954 | |
| > = 40 py | 205 | 1.636 | 0.933 | 2.867 | 0,086 | |
| pan-MAGE | negative | 237 | 1 | 1 | 1 | |
| positive | 162 | 1.234 | 0.913 | 1.669 | 0.172 | |
| negative | 237 | 1 | 1 | 1 | ||
| cyt OR nuc | 83 | 1.119 | 0.760 | 1.647 | 0,570 | |
| cyt + nuc | 79 | 1.356 | 0.938 | 1.961 | 0,105 | |
| MEI < 0.1 | 269 | 1 | 1 | 1 | ||
| MEI 0.1–0.39 | 86 | 1.107 | 0.768 | 1.597 | 0,585 | |
| MEI 0.4–0.69 | 18 | 1.582 | 0.827 | 3.025 | 0,165 | |
| MEI 0.7–1 | 9 | 1.301 | 0.53 | 3.189 | 0,566 | |
| MAGE-A3/A4 | negative | 244 | 1 | 1 | 1 | |
| positive | 155 | 1.320 | 0.976 | 1.786 | 0.072 | |
| negative | 245 | 1 | 1 | 1 | 0.129 | |
| cyt OR nuc | 73 | 1.242 | 0.835 | 1.846 | 0.285 | |
| cyt + nuc | 81 | 1.432 | 0.998 | 2.054 | 0.051 | |
| MEI < 0.1 | 281 | 1 | 1 | 1 | ||
| MEI 0.1–0.39 | 70 | 1.156 | 0.776 | 1.720 | 0.476 | |
| MEI 0.4–0.69 | 22 | 1.147 | 0.618 | 2.131 | 0.663 | |
| MEI 0.7–1 | 5 | 2.135 | 0.787 | 5.793 | 0.136 | |
| MAGE-A1 | negative | 324 | 1 | 1 | 1 | |
| positive | 76 | 1.011 | 0.691 | 1.478 | 0.957 | |
The comparators for each variable are signified by a HR of 1.
Abbreviations: T = T-classification, N = N-classification, M = M-classification, ECE = extracapsular extension, L = Lymphangiosis, V = vascular tumor emboli, R = resection margin status, HPV = human papilloma virus. n = absolute number of cases with available data, HR = hazard ratio, CI = confidence interval.